Immunovant Inc., a Roivant Sciences subsidiary, disclosed encouraging six-month off-treatment outcomes from a single-arm Phase II study of batoclimab in patients with uncontrolled Graves’ disease. The FcRn-targeting monoclonal antibody demonstrated meaningful activity, fueling anticipation for next-generation candidate IMVT-1402 currently in registrational trials. These data, highlighted at the American Thyroid Association's annual meeting, could significantly impact therapeutic options for autoimmune thyroid conditions.